Product profile
LOY-002 for dogs: eligibility, FDA status, mechanism, and evidence
A neutral, source-checked LOY-002 profile covering intended dogs, development status, safety milestones, mechanism claims, and unanswered questions.
Direct answer
LOY-002 is a once-daily prescription pill in development—not an over-the-counter supplement. Loyal says it is intended for dogs age 10 or older weighing at least 14 pounds and that two of three major technical sections for expanded conditional approval have been completed. Approval and availability were not confirmed in the primary sources reviewed through July 31, 2026.
The intended patient population
Loyal's current owner information describes LOY-002 for senior dogs age 10 or older that weigh at least 14 pounds. Those are development-program parameters, not a final FDA label. A final label could define indications, exclusions, dosing, warnings, and monitoring differently.
Age and weight alone cannot establish eligibility. Kidney or liver disease, current medications, cancer history, frailty, appetite changes, and other conditions may materially change a veterinarian's assessment. No page on this site can perform that assessment.
What the drug is designed to do
The sponsor says LOY-002 targets age-associated metabolic dysfunction and is intended to mimic some biological effects associated with caloric restriction without making a dog lose weight. That is a development hypothesis and mechanism claim. It is not a reason to restrict a dog's calories or combine products without veterinary supervision.
A plausible mechanism is not the same as a proven clinical benefit. The outcomes owners care about—healthy lifespan, mobility, cognition, disease burden, quality of life, and adverse events—must be measured in well-designed studies over time.
The regulatory milestones so far
Loyal reports that FDA accepted the reasonable-expectation-of-effectiveness technical section in 2025 and the Target Animal Safety technical section in December 2025. Its roadmap lists chemistry, manufacturing, and controls as the remaining major requirement before an expanded conditional approval decision.
Technical-section acceptance is meaningful progress, but it is not permission to sell. FDA explains that an actual conditional approval is a separate, time-limited status that permits legal marketing while the sponsor continues toward the substantial evidence required for full approval.
What remains unknown publicly
The primary pages reviewed do not provide a final FDA label, retail price, complete adverse-event table, final lifespan result, or individualized benefit estimate. Those gaps matter more than headline language.
- No confirmed launch date or dispensing instructions.
- No final public list of contraindications or drug interactions.
- No basis for promising a number of extra months or years to an individual dog.
- No equivalence between LOY-002 and products marketed as longevity supplements.
Frequently asked questions
Is LOY-002 available to buy?
Availability was not confirmed in the primary sources reviewed through July 31, 2026. Verify future status with FDA records, Loyal, and a veterinarian.
Is LOY-002 the same as LOY-001 or LOY-003?
No. They are separate development programs with different intended populations and dosage forms.
How long will LOY-002 make a dog live?
No responsible source can promise an individual lifespan gain. Publicly available final lifespan results were not established for this review.
Primary sources and limitations
Supports: Sponsor-reported intended populations, dosage form, development status, and the three major technical requirements described for LOY-002.
Limit: This is the developer's own product page, not independent confirmation of lifespan extension or an FDA approval listing.
Supports: Sponsor report that the reasonable expectation of effectiveness technical section was accepted for LOY-002.
Limit: RXE acceptance is not conditional approval, full approval, proof of sale, or a demonstrated individual outcome.
Supports: Sponsor report that FDA accepted the Target Animal Safety technical section for LOY-002 in December 2025.
Limit: The underlying FDA review package and complete study dataset are not supplied on this page.
Supports: The legal meaning of conditional approval, the reasonable-expectation-of-effectiveness standard, annual renewals, and the prohibition on extra-label use.
Limit: This explains the pathway. It is not a product-specific approval record for LOY-002.
Continue the evidence trail
Educational information only. This page does not diagnose, prescribe, or replace a veterinarian who knows your dog.